

ACC's Point of Care Tools: Quick Answers at your Fingertips

Shashank S. Sinha, MD

8 October 2016

Mexico City



ACC Latin America
Conference 2016

Disclosures

None: I am *still* a fellow-in-training



ACC Latin America
Conference 2016

Outline

- Background
- ACC's Collection of Point-of-Care Clinical Tools
 - ASCVD Risk Estimator
 - ACC Guideline App
 - Anticoag Evaluator
- Live Demo



Audience Response System

Do you use Point-of-Care apps in the office with your patients?

- A. Yes
- B. No
- C. Not Yet, But I Want To
- D. What's an App?



Survey Says ...

According to 2015 Survey of 500 professionals:

- 16% currently use mobile apps with patients → 46% plan to do so in next 5 years
- 86% believe mobile apps will increase knowledge of patients' conditions
- 46% believe apps will improve relationships with patients



ACC Latin America
Conference 2016

Mobile Devices and Apps for Health Care Professionals: Uses and Benefits

Table 1 Uses for Mobile Devices and Apps by Health Care Professionals

Information Management

- Write notes
- Dictate notes
- Record audio
- Take photographs
- Organize information and images
- Use e-book reader
- Access cloud service

Time Management

- Schedule appointments
- Schedule meetings
- Record call schedule

Health Record Maintenance and Access

- Access EHRs and EMRs
- Access images and scans
- Electronic prescribing
- Coding and billing

Communications and Consulting

- Voice calling
- Video calling
- Texting
- E-mail
- Multimedia messaging
- Video conferencing
- Social networking

Reference and Information Gathering

- Medical textbooks
- Medical journals
- Medical literature
- Literature search portals
- Drug reference guides
- Medical news

Clinical Decision-Making

- Clinical decision support systems
- Clinical treatment guidelines
- Disease diagnosis aids

- Differential diagnosis aids
- Medical calculators
- Laboratory test ordering
- Laboratory test interpretation
- Medical exams

Patient Monitoring

- Monitor patient health
- Monitor patient location
- Monitor patient rehabilitation
- Collect clinical data
- Monitor heart function

Medical Education and Training

- Continuing medical education
- Knowledge assessment tests
- Board exam preparation
- Case studies
- E-learning and teaching
- Surgical simulation
- Skill assessment tests



ACC Latin America
Conference 2016

<http://www.acc.org/tools-and-practice-support/mobile-resources#Clinical>

ACC's Clinical App Collection

Use these apps "on the go" to improve clinical knowledge and optimize patient care. To find the app you need, search by name in your app store, or visit **[ACC.org/Apps](https://www.acc.org/Apps)**.



CardioSmart Explorer



Statin Intolerance



FOCUS Imaging



ACC Guidelines



TAVR In-hospital Mortality Risk



AnticoagEvaluator



ASCVD Risk Estimator

Please Download Apps Now

<https://www.acc.org/tools-and-practice-support/mobile-resources>

- ASCVD Risk Estimator
- Anticoag Evaluator
- ACC Guideline App



ACC Latin America
Conference 2016

ACC Point-of-Care Clinical Apps



ACC Latin America
Conference 2016



2013 Prevention Guidelines ASCVD Risk Estimator

2013 Prevention Guidelines ASCVD Risk Estimator

ACC's First Open Access Journal is Now Live!

See the latest issue at
BasicTranslational.OnlineJACC.org



The ACC and the American Heart Association (AHA), in collaboration with the National Heart, Lung, and Blood Institute and other specialty societies, have released four guidelines focused on the assessment of cardiovascular risk, lifestyle modifications to reduce cardiovascular risk and management of elevated blood cholesterol and body weight in adults.

In order to support the implementation of these guidelines the ACC and AHA have jointly published a new mobile application (app).

The ASCVD Risk Estimator application helps health care providers and patients estimate 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD) using the Pooled Cohort Equations and lifetime risk prediction tools. The ASCVD Risk Estimator provides easy access to recommendations specific to calculated risk estimates. Additionally, the app includes readily accessible guideline reference information for both providers and patients related to therapy, monitoring, and lifestyle.

The app is available on both iTunes (iPhones, iPads) and Google Play (Galaxy, Nexus, other Android devices). Use the links below from your mobile device to download the app.

- [Click here to download the App From iTunes](#)
- [Click here to download the App From Google Play](#)
- [Click here to launch the Web Version](#)

<http://www.acc.org/tools-and-practice-support/mobile-resources/features/2013-prevention-guidelines-ascvd-risk-estimator>



The screenshots display the ASCVD Risk Estimator app interface. The top section shows the 'Estimator' tab with fields for 10-Year ASCVD Risk (13.3% calculated, 4.7% risk with optimal risk factors) and Lifetime ASCVD Risk (50% calculated, 5% risk with optimal risk factors). Below this is the 'Recommendation' section, which states 'Moderate to High-Intensity Statin Recommended' for adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL. The bottom section shows the 'Recommendations for Initiation of Statin Therapy' infographic, which provides a flowchart for determining statin therapy based on age, sex, and risk factors.

What is it?

- A companion tool to the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk.

- Enables health care providers and patients to estimate 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD) using the Pooled Cohort Equations and lifetime risk prediction tools.

- Provides Clinician and Patient references

Named the **top iPhone medical app** for the month of February by iMedicalApps

Where can I find it?

- Available for smartphones, tablets, and computers
- Download from the iTunes or GooglePlay App stores by searching “ascvd risk estimator”
- Or go to <http://tools.acc.org/ASCVD-Risk-Estimator/>



ACC Latin America
Conference 2016

For more information on ACC's complete family of mobile apps: <http://www.acc.org/tools-and-practice-support/mobile-resources>

ASCVD Risk Estimator*

All fields are required to compute ASCVD risk.

Gender

☒ Male☐ Female

Age

20-79

Race

☒ White☐ African American☐ Other

HDL - Cholesterol (mg/dL)

20-100

Total Cholesterol (mg/dL)

130-320

Systolic Blood Pressure

90-200

Diabetes

☒ Yes☐ No

Treatment for Hypertension

☒ Yes☐ No

Smoker

☒ Yes☐ No

*Intended for use if there is not ASCVD and the LDL-cholesterol is <190 mg/dL

**Optimal risk factors include: Total cholesterol of 170 mg/dL, HDL-cholesterol of 50 mg/dL, Systolic BP of 110 mm Hg, Not taking medications for hypertension, Not a diabetic, Not a smoker



Published jointly by ACC and AHA | © 2014

ACC Latin America
Conference 2016

10-Year ASCVD Risk Estimates

- Estimates of 10-year risk for ASCVD are based on data from *multiple* community-based populations
- Applicable to:
 - African-American and non-Hispanic white men and
 - Women 40 through 79 years of age
- For other ethnic groups, we recommend use of the equations for non-Hispanic whites
 - these estimates may underestimate the risk for persons from some race/ethnic groups



Lifetime ASCVD Risk Estimates

- Estimates of lifetime ASCVD risk are provided for *adults 20 through 59 years of age*
 - Shown as the lifetime risk for ASCVD for a 50-year old without ASCVD who has the risk factor values entered into the Estimator.
- Some Key Points:
 - The estimates of lifetime risk are most directly applicable to non-Hispanic whites.
 - We recommend the use of these values for other race/ethnic groups, though these estimates may represent under- and over-estimates for persons of various ethnic groups.
- Primary use of these lifetime risk estimates is to facilitate the very important discussion regarding risk reduction through lifestyle change
 - Thus, the imprecision introduced is believed to be small enough to justify proceeding with lifestyle change counseling informed by these results



ACC Latin America
Conference 2016

ASCVD Risk Estimator*

10-Year ASCVD Risk

8.2%
calculated risk5.2%
risk with optimal risk factors**

Lifetime ASCVD Risk

36%
calculated risk5%
risk with optimal risk factors

Recommendation Based On Calculation >

Gender

Male

Female

Age

59

Race

☒ White☐ African American☐ Other

HDL - Cholesterol (mg/dL)

40

Total Cholesterol (mg/dL)

170

Systolic Blood Pressure

130

Diabetes

Yes

No

Treatment for Hypertension

Yes

No

Smoker

Yes

No

*Intended for use if there is not ASCVD and the LDL-cholesterol is <190 mg/dL

**Optimal risk factors include: Total cholesterol of 170 mg/dL, HDL-cholesterol of 50 mg/dL, Systolic BP of 110 mm Hg, Not taking medications for hypertension, Not a diabetic, Not a smoker

ACC Latin America
Conference 2016



Based on the data entered (assuming no clinical ASCVD and LDL-C 70-189 mg/dL):

- Gender: Male
- Age: 59
- Race: White/Other
- Total Cholesterol: 170
- HDL-Cholesterol: 40
- Systolic Blood Pressure: 130
- Hypertension Treatment: No
- Diabetes: No
- Smoker: No

Moderate to High-Intensity Statin Recommended

Before initiating statin therapy, it is reasonable for clinicians and patients to engage in a discussion which considers the potential for ASCVD risk reduction benefits and for adverse effects, for drug-drug interactions, and patient preferences for treatment. (IIa C)

Adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL with no diabetes and estimated 10-year ASCVD risk $\geq 7.5\%$ should be treated with moderate to high-intensity statin therapy. (I A)

In individuals for whom after quantitative risk assessment a risk-based treatment decision is uncertain, additional factors may be considered to inform treatment decision making. These factors may include primary LDL-C ≥ 160 mg/dL or other evidence of genetic hyperlipidemias, family history of premature ASCVD with onset < 55 years of age in a first degree male relative or < 65 years of age in a first degree female relative, high-sensitivity C-reactive protein ≥ 2 mg/L, CAC score ≥ 300 Agatston units or ≥ 75 percentile for age, sex, and ethnicity, ankle-brachial index < 0.9 , or elevated lifetime risk of ASCVD. Additional factors may be identified in the future. (IIb C)



Reference

Clinician References

[Understanding Cardiovascular Risk](#)[Lifestyle Recommendations](#)[Groups that Benefit from Statin Therapy](#)[Blood Cholesterol Recommendation Summary](#)[Recommendations for Initiation of Statin Therapy](#)[Intensities of Statin Therapy](#)[Recommendations to Monitor Response to Statin Therapy](#)[Statin Safety Recommendations](#)[External Links to Full Guidelines & More Information](#)

Published jointly by ACC and AHA | © 2014



ACC Latin America
Conference 2016

Groups that Benefit from Statins

- + 1. Secondary Prevention: Clinical ASCVD**
- + 2. Primary Prevention: LDL-C ≥ 190 mg/dL**
- + 3. Primary Prevention: Diabetes and aged 40 to 75 years with LDL-C between 70 - 189 mg/dL**
- + 4. Primary Prevention: No diabetes and estimated 10-year ASCVD risk of $\geq 7.5\%$ who are between 40 to 75 years of age with LDL-C between 70 - 189 mg/dL**
- Additional Factors**

These factors may include:

Statin benefit may be less clear in other groups; additional factors may be considered to inform treatment decision making.

1. 5 to $< 7.5\%$ 10-year ASCVD risk
2. Primary LDL-C ≥ 160 mg/dL or other evidence of genetic hyperlipidemias
3. Family history of premature ASCVD
4. High sensitivity C-reactive protein ≥ 2 mg/L
5. Coronary artery calcium score ≥ 300 Agatston units or ≥ 75 th percentile for age, sex, and ethnicity
6. Ankle-brachial index < 0.9
7. Lifetime risk of ASCVD



Reference

Patient References

[Understanding My Cardiovascular Risk](#)[Diet and Physical Activity Recommendations](#)[Weight Management Recommendations](#)[Blood Cholesterol Management Recommendations](#)[Groups that Benefit from Statin Therapy](#)[Common Cardiovascular Terms](#)AMERICAN
COLLEGE of
CARDIOLOGYAmerican
Heart
Association

Published jointly by ACC and AHA | © 2014

ACC Latin America
Conference 2016

Blood Cholesterol Management Recommendations

The American College of Cardiology (ACC) and the American Heart Association (AHA) recently developed new standards for treating blood cholesterol. These recommendations are based on a thorough and careful review of the very latest, highest quality clinical trial research. They help care providers deliver the best care possible. This page provides some of the highlights from the new practice guidelines. The ultimate goal of the new cholesterol practice guidelines is to reduce a person's risk of heart attack, stroke and death. For this reason, the focus is not just on measuring and treating cholesterol, but identifying whether someone already has or is at risk for atherosclerotic cardiovascular disease (ASCVD) and could benefit from treatment.

What is ASCVD?

Heart attack and stroke are usually caused by atherosclerotic cardiovascular disease (ASCVD). ASCVD develops because of a build-up of sticky cholesterol-rich plaque. Over time, this plaque can harden and narrow the arteries.

These practice guidelines outline the most effective treatments that lower blood cholesterol in those individuals most likely to benefit. Most importantly, they were selected as the best strategies to lower cholesterol to help reduce future heart attack or stroke risk. Share this information with your health care provider so that you can ask questions and work together to decide what is right for you.

Key Points


Based on the most up-to-date and complete look at available clinical trial results:

- Health care providers should focus on identifying those people who are most likely to have a heart attack or stroke and make sure they are given effective treatment to reduce their risk.
- Cholesterol should be considered along with other factors known to make a heart attack or stroke more likely.
- Knowing your risk of heart attack and stroke can help you and your health care provider decide whether you may need to take a medication—most likely a statin—to lower that risk.
- If a medication is needed, statins are recommended as the first choice to lower heart attack and stroke risk among certain higher-risk patients based on an overwhelming amount of evidence. For those unable to take a statin, there are other cholesterol-lowering drugs; however, there is less research to support their use.









ACC Latin America
Conference 2016

ACC Point-of-Care Clinical Apps



ACC Latin America
Conference 2016



What is it?

- The App is the mobile home of ACC/AHA guideline content and tools for clinicians caring for patients with cardiovascular disease.
- Access guideline recommendations, “10 Points” summaries, and tools such as risk scores, calculators, and algorithms.
- Customize your App using the bookmark, note-taking and shareable PDF features.
- Currently includes Heart Failure, Afib, VHD, Cholesterol, CV Risk, Lifestyle, Obesity, NSTEMI, and Periop guidelines, with more slated for next year.

Where can I find it?

- Available for smartphones and tablets
- Download from the iTunes or GooglePlay App stores by searching “acc guidelines”
- More info at ACC.org/Guideline App



ACC Latin America
Conference 2016

For more information on ACC's complete family of mobile apps: <http://www.acc.org/tools-and-practice-support/mobile-resources>



Guideline Clinical App

Guideline Clinical App

Frequently Asked Questions



**ACC's First
Open Access
Journal is
Now Live!**

See the latest issue at
BasicTranslational.OnlineJACC.org

The ACC's Guideline Clinical App is the mobile home of clinical guideline content and tools for clinicians caring for patients with cardiovascular disease. You can access guideline recommendations, "10 Points" summaries, and tools such as risk scores, calculators and algorithms. Customize your App by using the bookmark, note-taking, and shareable PDF features.



The App is available for free in the iTunes (iPhone, iPad) and Google Play (Galaxy, Nexus, other Android devices) app stores. Use the links below from your mobile device to download the App.

[Download the App From iTunes](#)

[Download the App From Google Play](#)

The App currently offers content for the following guidelines:

- Atrial Fibrillation
- Cardiovascular Risk
- Coronary Artery Bypass Graft
- Cholesterol
- Device-Based Therapy
- Dual Antiplatelet Therapy Update
- Heart Failure
- Lifestyle
- Non-ST-Elevation Acute Coronary Syndromes
- Obesity
- Percutaneous Coronary Intervention
- Perioperative Management for Noncardiac Surgery
- Stable Ischemic Heart Disease
- ST-Elevated Myocardial Infarction
- Supraventricular Tachycardia
- Valvular Heart Disease

Guideline Clinical Apps

My Tools

Chol

CV Risk

HF

AF

VHD

Lstyle

Obesity

NSTEMI

Periop

DBT

SVT

DAPT Update

PCI

STEMI

SIHD

CABG

Home

Menu

Back

Forward

Search

Edit

Star

Info

Heart Failure (w/ 2016 Updt)

< HF Patient Evaluation >

< Biomarkers


Edit

Star

>

Ambulatory/Outpatient

Recommendations	COR	LOE
In ambulatory patients with dyspnea, measurement of B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) is useful to support clinical decision making regarding the diagnosis of HF, especially in the setting of clinical uncertainty.	I	A
Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic HF	I	A



[Back](#)

Interactive Tools

Stage C HFrEF Medical
Therapy [HF]

**Persistently Symptomatic African Americans,
NYHA class III-IV?**

No

Yes

Stage C HFrEF: evidence-based, guideline-directed
medical therapy.

[Abbreviations](#)

ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; HFrEF = heart failure with reduced ejection fraction; Hydral-Nitrates = hydralazine and isosorbide dinitrate; LOE = Level of Evidence; and NYHA = New York Heart Association.

ACC Latin America
Conference 2016[Back](#)

Interactive Tools

ASCVD Risk Estimator
[Chol/CV Risk]

RECOMMENDATIONS:

Based on the data entered above
(assuming no clinical ASCVD and LDL-C
70-189 mg/dL):

Consider high-intensity statin Moderate-
intensity statin therapy should be initiated
or continued for adults 40 to 75 years of
age with diabetes mellitus. (I A)

High-intensity statin therapy is reasonable
for adults 40 to 75 years of age with
diabetes mellitus with a $\geq 7.5\%$ estimated
10-year ASCVD risk unless
contraindicated. (IIa B)

It is reasonable to evaluate the potential
for ASCVD benefits and for adverse
effects, for drug-drug interactions, and to

ACC Point-of-Care Clinical Apps



ACC Latin America
Conference 2016

AnticoagEvaluator App

AnticoagEvaluator App

FAQ



**ACC's First
Open Access
Journal is
Now Live!**

See the latest issue at
BasicTranslational.Online.JACC.org

The updated AnticoagEvaluator helps clinicians make informed decisions on antithrombotic therapy for their non-valvular AF patients.

Use the app to:

- Calculate a patient's stroke risk (CHA2DS2-Vasc), bleed risk (HAS-BLED and concomitant meds), and renal function (Cockcroft-Gault Equation)
- Review stroke prevention therapy guidance based on ACC/AHA/HRS's 2014 Guidelines for the Management of Patients with Atrial Fibrillation
- Improve accurate use of DOACs with adjusted dosage based on prescribing information, fine-tuned for renal and other patient characteristics
- Determine appropriate therapy for a patient by reviewing
 - Synthesized individualized risk for antithrombotic therapy options based on clinical trials (e.g., ACTIVE-A, RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE-AF)
 - Relevant safety information and full prescribing information for all therapy options



If you had downloaded the previous AnticoagEvaluator version on your iPhone or iPad before December 2015, simply update the app on your Apple device to access the updated version. For all other users, this update app is available for free on the web, and in the iTunes and Google Play app stores. Use the links below to access the app today.

[Download the App
From iTunes >>>](#)

[Download the App
From Google Play >>>](#)

[Launch the
Web Version >>>](#)

<http://www.acc.org/tools-and-practice-support/mobile-resources/features/anticoag-evaluator>

This app was developed as part of ACC's Anticoagulation Initiative and is an update to the original AnticoagEvaluator App. Its content was adapted from a web tool created by Peter Loewen, ACPR, Pharm.D., FCSHP, which can be viewed at <http://www.sparctool.com/>.



Calculate Risk **Review Therapy**

Stroke Risk **1** CHA₂DS₂-VAsC
Intermediary risk

Renal Function **0.4** CrCl
mg/dL mL/min

CHA₂DS₂-VAsC

Select all that apply

- ☐ CHF/LV dysfunction ⓘ
- ☒ Hypertension ⓘ
- ☐ Age ≥ 75 yrs
- ☐ Diabetes mellitus
- ☐ Stroke/TIA/TE ⓘ
- ☐ Vascular disease ⓘ
- ☐ Age 65-74 yrs
- ☐ Sex: Female

Calculate Risk **Review Therapy**

Stroke Risk **1** CHA₂DS₂-VAsC
Intermediary risk

Renal Function **0.4** CrCl
mg/dL mL/min

Creatinine Clearance
(Cockcroft-Gault Equation)

All four values are required to calculate Creatinine Clearance

Select Units ☐ SI ☒ US

Age Yrs

Sex

Weight

Calculate Risk **Review Therapy**

Stroke Risk **1** CHA₂DS₂-VAsC
Intermediary risk

Renal Function **0.4** CrCl
mg/dL mL/min

Bleed Risk Considerations

Consider a patient's bleed risk when evaluating for anticoagulation therapy, and minimize bleed risk whenever possible.

Select all that apply

HAS-BLED ⓘ **SCORE: 1**

- ☒ Hypertension
- ☐ Abnormal Renal Function
- ☐ Abnormal Liver Function
- ☐ Stroke/TIA/TE

Calculate Risk **Review Therapy**

Stroke Risk **1** CHA₂DS₂-VAsC
Intermediary risk

Renal Function **0.4** CrCl
mg/dL mL/min

222.2 CrCl
mL/min

Review Therapy

1 Consider Therapy Guidance ⓘ

The following therapy options may be considered due to intermediate stroke risk:

- No antithrombotic therapy
- Aspirin
- Oral anticoagulant

Calculate Risk **Review Therapy**

Stroke Risk **1** CHA₂DS₂-VAsC
Intermediary risk

Renal Function **0.4** CrCl
mg/dL mL/min

222.2 CrCl
mL/min

2 Select Therapy Option

Please select

Anticoagulants (by alpha order)

- Aspirin
- Aspirin + Clopidogrel

Anticoagulants (by alpha order)

- Apixaban
- Dabigatran
- Edoxaban

Calculate Risk **Review Therapy**

Stroke Risk **1** CHA₂DS₂-VAsC
Intermediary risk

Renal Function **0.4** CrCl
mg/dL mL/min

222.2 CrCl
mL/min

3 Evaluate Therapy

Standard Dose 150 mg twice daily (clinical trials)

Risk/Benefit Information*

Patient's ANNUAL risk of stroke + thromboembolism with Dabigatran 0.3%

Relative risk reduction	79%
Absolute risk reduction	1.2%
Chance of benefit per year	1 in 85

What is it?

Helps clinicians assess the best antithrombotic therapy for their patient by:

- Calculating patient's stroke risk, bleed risk, and renal function
- Offering tailored ACC/AHA-guideline-based guidance
- Providing auxiliary information about each therapy, including
 - risk and benefit data
 - standard and renal-adjusted dosing
 - safety and prescribing information

Where can I find it?

- Available for smartphones, tablets, and computers
- Download from the iTunes or GooglePlay App stores by searching "**anticoagevaluator**"
- Or go to <http://tools.acc.org/anticoag>



ACC Latin America
Conference 2016

For more information on ACC's complete family of mobile apps: <http://www.acc.org/tools-and-practice-support/mobile-resources>



Anticoag Evaluator

Calculate Risk

Review Therapy

Stroke Risk

CHA₂DS₂-VASc

Renal Function

SCr
mg/dL

CrCl
mL/min

Calculate Risk Reset All

Patient Information

Required to derive therapy options

Age
 Yrs

Sex

Please select ▼

CHA₂DS₂-VASc

Make informed decisions on antithrombotic therapy for your non-valvular AF patients.

Calculate Risk

Review Therapy

Stroke Risk

CHA₂DS₂-VASc
4
High risk

Renal Function

SCr
mg/dL
0.6

CrCl
mL/min
128.0

☒ Hypertension ⓘ

☐ Age ≥ 75 yrs

☐ Diabetes mellitus

☒ Stroke/TIA/TE ⓘ

☐ Vascular disease ⓘ

☒ Age 65-74 yrs

☐ Sex: Female

Creatinine Clearance

(Cockcroft-Gault Equation)

All four values are required to calculate

Calculate a patient's stroke risk, bleed risk, and renal function.

Calculate Risk	Review Therapy
4 CHA ₂ DS ₂ -VASc High risk	0.6 sCr mg/dL
	128.1 CrCl mL/min

1 Consider Therapy

Guidance ⓘ

Oral anticoagulation therapy recommended due to high stroke risk

2 Select Therapy Option

Please select

Please select

No Therapy

Antiplatelets (by alpha order)

Aspirin

Aspirin + Clopidogrel

Anticoagulants (by alpha order)

Apixaban

Dabigatran

Edoxaban

Rivaroxaban

Warfarin

Review guidance from ACC/AHA/HRC's 2014 Atrial Fibrillation Guideline and select from a full range of therapy options.

Calculate Risk	Review Therapy
4 CHA ₂ DS ₂ -VASc High risk	0.6 sCr mg/dL
	128.0 CrCl mL/min

2 Select Therapy Option

Edoxaban

3 Evaluate Therapy

Renal-Function
Adjusted Dose

Contraindicated ⓘ

Stroke Risk/
Benefit

Bleed
Risk

Safety
Info

Risk/Benefit Information*

Patient's ANNUAL risk of stroke + thromboembolism with Edoxaban

Relative risk reduction 66%

Absolute risk reduction 4.4%

Review adjusted dosage based on prescribing information and synthesized risk for antithrombotic therapy options based on clinical trials.



Statin Intolerance

Eval Follow Up Compare

Welcome to ACC's Statin Intolerance Tool

This tool should be used by clinicians to assess, treat, and manage patients with possible statin intolerance.

Although muscle symptoms may occur, true statin intolerance is uncommon. Given the benefits of statins in ASCVD risk reduction, clinicians should partner with the patient to gain a thorough symptom history and determine if he or she is truly statin intolerant. Walk through the steps of treating and managing a patient who reports muscle symptoms, including cycles of statin discontinuation and re-challenge to identify a tolerated statin and dose.

1 Evaluate

Eval Follow Up Compare

Back to Follow Up Reasons

Patient has been re-challenged with original statin

Current Follow Up

Did muscle symptoms come back after rechallenge?

Yes No

Recommendation

Next Steps

- Stop original statin.
- Wait for muscle symptoms to resolve again.

Intolerance
Muscle ache, Weakness, Soreness, Stiffness, Cramping, Tenderness, General Fatigue

Any from this group - Unlikely intolerance
Tingling, Twitching, Shooting Pain, Nocturnal Cramps, Joint Pain

Select symptom area.

Bilateral - Possible intolerance
Patient's muscle symptoms are generalized (e.g., neck and shoulder pain, lower extremity pain)

Unilateral - Unlikely intolerance
Patient's muscle symptoms are isolated (e.g. knee or shoulder ache)

Select patient's indicated symptom severity.

Severe/Intolerant Mild/Moderate/Tolerant

Statin-Related Muscle Symptoms

Value	Result	Possible	Unlikely
Symptom timing allows for statin intolerance	Yes		
Symptom Type	Muscle ache, Weakness, Soreness, Stiffness, Cramping, Tenderness, General Fatigue	✓	
Symptom Location	Bilateral	✓	
Age	>75 predisposes to statin adverse effects	✓	
Race/Ethnicity	Asian ancestry predisposes to statin adverse effects. May need to lower dose or alternate statin	✓	
CK Elevated > 5x	Don't know		

***** ATAT LTE 12:39 PM

Secondary Drug Warnings

The tables below are compiled only from the following sources and may not represent all possible interactions. Prescribing information, Expert Opinion, & FDA Recommendation. * ACC/LANA Guideline Recommendation

Statin's Interactions with Drugs You Have Selected

Drug	Interaction
Amiodarone (selected)	May require lower starting and maintenance dose of atorvastatin
Diltiazem (selected)	May increase atorvastatin exposure; monitor for muscle symptoms
Niacin ≥ 1 g/day (selected)	Use caution with concomitant use. To reduce the frequency and severity of adverse cutaneous flushing symptoms, it is reasonable to start niacin at a low dose and increase dose gradually over a period of weeks as tolerated. Take niacin with food.

***** ATAT LTE 12:39 PM

Primary Metabolism

Atorvastatin (Lipitor®)	CYP3A4
Fluvastatin (Lescol®)	(75%) CYP2C9; (5%) CYP2C8; and 20% CYP3A4
Fluvastatin XL (Lescol XL®)	(75%) CYP2C9; (5%) CYP2C8; and 20% CYP3A4
Lowastatin (Mevacor®)	CYP3A4
Pitavastatin (Livalo®)	Minimal CYP2C9 and CYP2C8
Pravastatin (Pravachol®)	Minimal CYP450 metabolism
Rosuvastatin (Crestor®)	Minimal CYP2C9
Simvastatin (Zocor®)	CYP3A4



Statin Intolerance

Recommend Terms About

What is it?

The ACC Statin Intolerance App guides clinicians through the process of managing and treating patients who report muscle symptoms while on statin therapy.

- Answer questions to evaluate possible intolerance to a patient's current statin prescription.
- Follow steps to manage and treat a patient who reports muscle symptoms on a statin.
- Compare statin characteristics and drug interactions to inform management of LDL-related risk.

Where can I find it?

- Available for smartphones, tablets, and computers
- Download from the iTunes or GooglePlay App stores by searching "acc statin intolerance"
- Or go to <http://tools.acc.org/statinintolerance>

This app was developed as part of the ACC's LDL: Address the Risk Initiative. Financial support for the LDL: Address the Risk Initiative was provided by Amgen Inc. All of the content was independently developed with no sponsor involvement.



ACC Latin America Conference 2016

For more information on ACC's complete family of mobile apps: <http://www.acc.org/tools-and-practice-support/mobile-resources>



Calculate Risk

* All parameters are required to derive the adjusted TAVR in-hospital mortality risk

Patient Demographics

Age (18-100): 57 Years

Sex: Male

Race: Black or African American

Patient Pre-Procedural Characteristics

Renal Function: Glomerular Filtration Rate (calculated): 90 mL/min/1.73m²

Select Units: SI ☐ US ☒

Serum Creatinine (SCr): 0.4 mg/dL

Currently on Dialysis? Yes ☐ No ☒

Procedure Access Site: Femoral

NYHA Class IV within 2 weeks? Yes ☐ No ☒

Acuity Status

Acuity Status: Category 4

Procedure Status: Urgent

Prior cardiac arrest: Yes ☒ No ☐

Prior cardiogenic shock: Yes ☐ No ☒

Pre-procedure inotropes: Yes ☐ No ☒

Mechanical assist device: Yes ☐ No ☒

Adjusted TAVR In-Hospital Mortality Risk

Click here for info about this risk model

Patient's Risk: 2% National Average: 4% as of May 2015

In the United States, the average mortality of all patients undergoing this procedure is 4%. Taking into account the patient's specific clinical condition, the statistical estimate that he might not survive the procedure is 2%. This means that for every 100 patients having a similar clinical makeup, there would be 2 who did not survive.

The model provides an objective risk-adjusted estimate of in-hospital mortality which has real value for both patient and provider. It should be considered as one element in the evaluation process, to be considered along with the other traditional factors that determine whether the

Based on following evaluation

Patient Demographics

Age: 57 Years Sex: Male

Race: Black or African American

Patient Pre-Procedural Characteristics

Renal Function: Glomerular Filtration Rate (calculated): 90 mL/min/1.73m²

Serum Creatinine (SCr): 0.4 mg/dL

Dialysis: Yes ☐ No ☒

NYHA Class IV: Yes ☐ No ☒

Severe Chronic Lung Disease: Yes ☐ No ☒

Procedure Access Site: Femoral

Acuity Status Category 4

Procedure Status: Urgent

Prior Cardiac arrest within 24 hrs? Yes ☒

Prior cardiogenic shock within 24 hrs? Yes ☐ No ☒

Pre-procedure inotropes within 24 hrs? Yes ☐ No ☒

Pre-procedure mechanical assist device? Yes ☐ No ☒

Email Results

What is it?

- The STS/ACC TAVR In-Hospital Mortality Risk App informs physicians of the estimated risk of in-hospital mortality for patients considering transcatheter aortic valve replacement as a treatment option.

- Physicians can compare individual patient risk to the national average based on data from the STS/ACC TVT Registry™.

- The app facilitates consistent risk assessment and communication between a physician and patient about TAVR.

Where can I find it?

- Available for smartphones, tablets, and computers
- Download from the iTunes or GooglePlay App stores by searching “acc tavr app”
- Or go to <http://tools.acc.org/tavrisk>



ACC Latin America
Conference 2016

For more information on ACC's complete family of mobile apps: <http://www.acc.org/tools-and-practice-support/mobile-resources>.



Evaluate **Advice**

Evaluate

* Answer each question in the series below to view Advice. [Reset All](#)

Select intended use

- ☒ 3a. Primary prevention ICD
- ☐ 3b. Secondary prevention ICD
- ☐ 3c. Dual-chamber ICD (must first meet Appropriate or May Be Appropriate AUC score for primary or secondary prevention ICD)
- ☐ 3d. CRT - no prior implant
- ☐ 3e. Generator replacement at elective replacement indicator (ERI)

Select LVEF range

- ☐ 1a. $\leq 30\%$ (severe)
- ☒ 1b. 31-35% (moderate-to-severe)
- ☐ 1c. 36-40% (mild)
- ☐ 1d. 41-49% (mild)

Advice

Appropriate use advice for:

A Appropriate

ICD for PRIMARY PREVENTION
(ACC ICD #115)
[Click here to view full ACC AUC document](#)

For a patient with:

- LVEF $\leq 35\%$
- nonischemic cardiomyopathy
- myotonic dystrophy

[View Less](#)

[Evaluate](#) [Email Advice](#)

Advice

CMS Coverage Advice (Medicare)

COVERAGE CAN BE EXPECTED for a patient with:

- Non-ischemic dilated cardiomyopathy > 3 months, with
 - LVEF $\leq 35\%$
 - NYHA Class II or III heart failure

ONLY IF these ADDITIONAL CRITERIA are met:

Patient MUST NOT HAVE ANY of the following...

Cardiovascular conditions

- Acute MI ≤ 40 days
- Clinical indications that would make them a candidate for **coronary revascularization** OR
- CABG or PTCA within past 3 months OR
- Cardiogenic shock or hypotension while in stable baseline rhythm

Other conditions

- Irreversible **brain damage** from preexisting cerebral disease OR
- Any noncardiac disease

What is it?

ICD-CRT Appropriate Use Criteria App provides decision and documentation support for clinicians assessing the appropriateness of device implantation for their patients.

- Record intended device and patient's clinical indications.
- Obtain procedure appropriate use rating according to ACC/HRS et al's 2013 Appropriate Use Criteria for ICD and CRT document.
- View suggested likelihood of CMS coverage for an ICD based on 2005 CMS Coverage Determination criteria.
- Email yourself a record of patient inputs and the corresponding AUC and CMS advice.

Where can I find it?

- Available for smartphones, tablets, and computers
- Download from the iTunes or GooglePlay App stores by searching "**acc icd appropriate use**"
- Or go to http://tools.acc.org/ICD_AUC



ACC Latin America
Conference 2016

For more information on ACC's complete family of mobile apps: <http://www.acc.org/tools-and-practice-support/mobile-resources>

Help Us Help You

Provide Feedback

- Leave your comments in the iTunes or Google Play page for the app
- Fill out ACC's official feedback survey located in the "About the App" section within most of the apps

Become an App Tester

- Test out the apps as part of the development process by contacting Erin Schmieder

eschmieder@acc.org



ACC Latin America
Conference 2016

Now the real fun begins ...



ACC Latin America
Conference 2016

Audience Response System



ACC Latin America
Conference 2016

Case Presentation #1

A 52-year-old African American woman presents to establish cardiovascular care. She is active and asymptomatic. She has long-standing HTN on lisinopril 20 mg daily but no known history of DM or family history of premature CAD. She is a lifelong never smoker. VS: BP 135/85 HR 72. BMI 25. Recent lipid profile: Chol 202 TG 150 LDL 128 HDL 44.



Which of the following is the best next step in management?

- A. Advise heart healthy diet and regular aerobic exercise
- B. Consider adding atorvastatin 20 mg daily
- C. Consider adding rosuvastatin 40 mg daily
- D. A and B
- E. A and C



Which of the following is the best next step in management?

- A. Advise heart healthy diet and regular aerobic exercise
- B. Consider adding atorvastatin 20 mg daily
- C. Consider adding rosuvastatin 40 mg daily
- D. A and B**
- E. A and C



ASCVD Risk Estimator*

10-Year ASCVD Risk

6.4%
calculated risk1.3%
risk with
optimal risk
factors**

Lifetime ASCVD Risk

39%
calculated risk8%
risk with
optimal risk
factors

Recommendation Based On Calculation >

Gender

Male

Female

Age

52

Race

☐ White☒ African American☐ Other

HDL - Cholesterol (mg/dL)

44

Total Cholesterol (mg/dL)

202

Systolic Blood Pressure

135

Diabetes

Yes

No

Treatment for Hypertension

Yes

No

Smoker

Yes

No

*Intended for use if there is not ASCVD and the LDL-cholesterol is <190 mg/dL

**Optimal risk factors include: Total cholesterol of 170 mg/dL, HDL-cholesterol of 50 mg/dL, Systolic BP of 110 mm Hg, Not taking medications for hypertension, Not a diabetic, Not a smoker

ACC Latin America
Conference 2016

- Race: African American
- Total Cholesterol: 202
- HDL-Cholesterol: 44
- Systolic Blood Pressure: 135
- Hypertension Treatment: Yes
- Diabetes: No
- Smoker: No

Consider Moderate-Intensity Statin

Before initiating statin therapy, it is reasonable for clinicians and patients to engage in a discussion which considers the potential for ASCVD risk reduction benefits and for adverse effects, for drug-drug interactions, and patient preferences for treatment. (IIa C)

It is reasonable to offer treatment with a moderate-intensity statin to adults 40 to 75 years of age with no diabetes and 10-year risk of of 5% to <7.5%. (IIa B)

In individuals for whom after quantitative risk assessment a risk-based treatment decision is uncertain, additional factors may be considered to inform treatment decision making. These factors may include primary LDL-C ≥ 160 mg/dL or other evidence of genetic hyperlipidemias, family history of premature ASCVD with onset <55 years of age in a first degree male relative or <65 years of age in a first degree female relative, high-sensitivity C-reactive protein ≥ 2 mg/L, CAC score ≥ 300 Agatston units or ≥ 75 percentile for age, sex, and ethnicity, ankle-brachial index <0.9, or elevated lifetime risk of ASCVD. Additional factors may be identified in the future. (IIb C)

Lifestyle Recommendations

AHA/ACC guidelines stress the importance of lifestyle modifications to lower cardiovascular disease risk. This includes eating a heart-healthy diet, regular aerobic exercises, maintenance of desirable body weight and avoidance of tobacco products.



Case Presentation #2

A 81-year-old woman with well-controlled HTN, DMII and Stage IV CKD (SCr 1.3 mg/dl) presents to your clinic 2 weeks after discharge for new onset paroxysmal atrial fibrillation. Her rate is well-controlled with metoprolol tartrate 25 mg twice daily. VS: BP 100/60 HR 62. Weight 120 lbs. Her meds include ASA 81 mg daily and Ibuprofen 400 mg BID prn knee pain. She seeks your input regarding anticoagulation.



Which of the following is the best next step in management?

- A. Aspirin 325 mg daily
- B. Aspirin 81 mg daily + Clopidogrel 75 mg daily
- C. Apixaban 2.5 mg twice daily
- D. No antiplatelet or anticoagulant therapy



Which of the following is the best next step in management?

- A. Aspirin 325 mg daily
- B. Aspirin 81 mg daily + Clopidogrel 75 mg daily
- C. Apixaban 2.5 mg twice daily
- D. No antiplatelet or anticoagulant therapy





Stroke Risk

5 ^{CHA₂DS₂-VASc}
High risk

Renal Function

1.3 ^{SCr} **29.2** ^{CrCl}
mg/dL mL/min

CHA₂DS₂-VASc

Select all that apply



CHF/LV dysfunction ⓘ



Hypertension ⓘ



Age ≥ 75 yrs



Diabetes mellitus



Stroke/TIA/TE ⓘ



Vascular disease ⓘ



Age 65-74 yrs



Sex: Female

Creatinine Clearance (Cockcroft-Gault Equation)

All four values are required to calculate Creatinine Clearance

Select Units

SI

☒ US

Age

81

Yrs

Sex

Female





Stroke Risk

5 ^{CHA₂DS₂-VASc}
High risk

Renal Function

1.3 ^{SCr} **29.2** ^{CrCl}
mg/dL mL/min

Bleed Risk Considerations

Consider a patient's bleed risk when evaluating for anticoagulation therapy, and minimize bleed risk whenever possible.

Select all that apply

HAS-BLED ⓘ

SCORE: 4

☒ Hypertension

☐ Stroke/TIA/TE

☒ Age > 65 yrs

☒ Abnormal Renal Function

☐ History of Major Bleeding

☐ Current "excess" of Alcohol

☐ Abnormal Liver Function

☐ History of Labile INR

☒ Currently taking antiplatelet drugs or NSAIDs

Concomitant Medications

☒ Aspirin (any dose)

☐ P2Y12 Inhibitors ⓘ

☒ NSAIDs

☐ Other antiplatelets ⓘ





5 CHA₂DS₂-VASc
High risk

1.3 SCr
mg/dL

29.2 CrCl
mL/min

1 Consider Therapy Guidance ⓘ

Oral anticoagulation therapy recommended due to high stroke risk

2 Select Therapy Option

No Therapy ▼

3 Evaluate Therapy

Standard Dose (clinical trials)

Not applicable

Stroke Risk/Benefit

Bleed Risk

Safety Info

Risk/Benefit Information*

Patient's ANNUAL risk of stroke + thromboembolism with No Therapy

10.0%





5 ^{CHA₂DS₂-VASc}
High risk

1.3 ^{SCr}
mg/dL

29.2 ^{CrCl}
mL/min

③ Evaluate Therapy

Renal-Function Adjusted Dose

2.5 mg twice daily ⓘ

Stroke Risk/Benefit

Bleed Risk

Safety Info

Risk/Benefit Information*

Patient's ANNUAL risk of stroke + thromboembolism with Apixaban	2.6%
Relative risk reduction	74%
Absolute risk reduction	7.4%
Chance of benefit per year	1 in 14

Based on SPARC Tool developed by Peter Loewen, ACPR, Pharm.D., FCSHP

*This table refers to Apixaban (5 mg twice daily) and calculates individualized annual risk of ischemic stroke and thromboembolism using relative risk reduction from the clinical trials in combination with individual risk factors. This data is not the result of head-to-head trials.



Acknowledgements

- Andrew Freeman, MD, FACC
- Robert Harrington, MD, MACC
- Erick Alexanderson Rosas, MD, FACC
- Outstanding ACC Staff



ACC Latin America
Conference 2016

Muchas Gracias!



Questions?



ACC Latin America
Conference 2016



ACC Latin America Conference 2016

MEXICO CITY

OCTOBER 7 – 8, 2016

For more information, visit
ACC.org/LatinAmerica2016



UNIQUE EDUCATIONAL EXPERIENCE
IN YOUR REGION